Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Antifungal agents from Hokko Kagaku

Aug. 30, 1996

Dura obtains marketing rights of Lilly's cephalosporin antibiotics

Aug. 30, 1996

Erythromycin A 9-O-oxime derivatives from Zambon

Aug. 23, 1996

SR-3775: Promising candidate for cytomegalovirus disease treatment

Aug. 23, 1996

GEM-132 enters phase I safety and pharmacokinetic trial

Aug. 23, 1996

SmithKline Beecham describes protease inhibitors

Aug. 23, 1996

Isis now fully owns fomivirsen

Aug. 23, 1996

Solvay to copromote Famvir in U.S.

Aug. 23, 1996

Sequus and Torrex Pharma sign Amphotec marketing agreement

Aug. 23, 1996

Xoma granted permission to commence phase III for rBPI21

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...